| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2017 | V Bryan Lawlis53 | Director | Sale+OE | 3,750 | $90.00 | $337,500.00 | -19.1% | |
| Jun 7, 2017 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 1,004 | $89.61 | $89,968.44 | -2.1% | |
| Jun 5, 2017 | George Eric Davis65 | EVP, General Counsel | Sell | 9,471 | $91.04 | $862,230.37 | -11.3% | |
| Jun 5, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 10,000 | $90.13 | $901,300.00 | -4.2% | |
| Jun 1, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 5,000 | $87.53 | $437,650.00 | -2.1% | |
| May 31, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 7,423 | $88.29 | $655,376.67 | -3.1% | |
| May 24, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 5,000 | $88.38 | $441,900.00 | -2.1% | |
| May 17, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 5,000 | $91.73 | $458,650.00 | -2.1% | |
| May 12, 2017 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 5,000 | $89.23 | $446,150.00 | -2.1% | |
| May 8, 2017 | Brian Mueller64 | SVP, Corporate Controller | Sale+OE | 7,482 | $91.87 | $687,333.94 | -35.7% |